Tests rimegepant to prevent chronic migraine in adults
Tests a daily pill, rimegepant, against placebo in adults with chronic migraine.
Key facts
- Who runs it
- Pfizer
- Where
- Ann Arbor, Austin, Boca Raton, Canoga Park, City of Saint Peters, Dallas, Fresno, Indianapolis, Los Angeles, Memphis, Oklahoma City, Overland Park, Papillion, Salt Lake City, Scottsdale, Williamsville, Winter Park, and Worcester, United StatesSee the 19 sitesAlso in 1 other country, 2 sites
- Trial code
- Registry title
- A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 400 people, planned
- Started
- 26 Aug 2026
- Expected to end
- 19 Jan 2029
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Rimegepant
- Placebo
- Record updated
- 14 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with chronic migraine for at least 1 year. It tests once-daily rimegepant against placebo to prevent migraine.
- Age
- 18 years or older
- Sex
- Women and men can join.
- Disease stage
- Chronic migraine, with or without aura. In the 3 months before screening, an average of at least 15 headache days a month, including at least 8 migraine days, and at least 1 headache-free day a month. Migraine began before age 50 and chronic migraine before age 65. Untreated attacks last 4 to 72 hours.
- Earlier treatment
- People who used rimegepant before to prevent migraine cannot join. People for whom 2 gepants, 2 CGRP-targeting biologics, or 1 gepant plus 1 CGRP-targeting biologic failed cannot join. Failure of more than 4 migraine preventive medicines also rules people out.
Main reasons for not taking part
- Earlier use of rimegepant to prevent migraine
- Failed treatment with 2 gepants, 2 CGRP-targeting biologics, or 1 of each
- Failure of more than 4 migraine preventive medicines
- Pregnant, breastfeeding, or planning pregnancy or breastfeeding during the study
- A health problem the investigator judges risky, such as uncontrolled hypertension or Raynaud's phenomenon
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Male or female participants ≥18 years of age
- Diagnosis of chronic migraine, with or without aura, according to International Classification of Headache Disorders, 3rd edition (ICHD-3) criteria
- History of migraine for at least 1 year before screening
- Migraine onset before 50 years of age and chronic migraine onset before 65 years of age
- Migraine attacks lasting 4 to 72 hours when untreated or unsuccessfully treated
- During the 3 months prior to screening, an average of:
- ≥15 monthly headache days (MHDs),
- including ≥8 monthly migraine days (MMDs),
- and ≥1 non-headache day per month
- Completion of the Observation Phase and fulfillment of all protocol-defined eligibility requirements prior to randomization
- Willing and able to comply with study procedures, including completion of the electronic diary
Who cannot take part
- Prior use of rimegepant for migraine prevention
- Positive amphetamine screening result unless attributable to prescribed stimulant therapy that has been stable for at least 3 months prior to Visit 1 and is expected to remain stable throughout study participation
- Use of investigational products or participation in another clinical study within protocol-defined exclusion windows
- History of treatment failure of:; 2 gepants, or; 2 CGRP-targeting biologics, or; 1 gepant and ≥1 CGRP-targeting biologic
- Failure of >4 migraine preventive medications, including at least 2 with different mechanisms of action
- Any other condition that, in the opinion of the investigator or sponsor, would make study participation unsafe or compromise study conduct
- Any medical or psychiatric condition, or clinically significant laboratory abnormality, that in the investigator's judgment may increase risk to the participant or interfere with study participation or interpretation of results. This includes, but is not limited to, uncontrolled hypertension or a history of Raynaud's phenomenon
- Pregnant, breastfeeding, planning to become pregnant, or planning to initiate breastfeeding during the study
Where in United States
Also in 1 other country, 2 sites
- Michigan Headache & Neurological InstituteAnn Arbor, United StatesTaking people
- Austin Clinical Trial PartnersAustin, United StatesTaking people
- FutureSearch Trials of NeurologyAustin, United StatesTaking people
- Neurology Offices of South Florida PLLCBoca Raton, United StatesTaking people
- Hope Clinical ResearchCanoga Park, United StatesTaking people
- StudyMetrix ResearchCity of Saint Peters, United StatesTaking people
- FutureSearch Trials of DallasDallas, United StatesTaking people
- Neuro Pain Research CenterFresno, United StatesTaking people
- Josephson Wallack Munshower Neurology, PCIndianapolis, United StatesTaking people
- Clinical Research InstituteLos Angeles, United StatesTaking people
- Clinical Neuroscience Solutions, LLC.Memphis, United StatesTaking people
- Hightower ClinicalOklahoma City, United StatesTaking people
- Collective Medical ResearchOverland Park, United StatesTaking people
- Papillion Research Center/AvacarePapillion, United StatesTaking people
- Highland Clinical ResearchSalt Lake City, United StatesNot yet recruiting
- Clinical EndpointsScottsdale, United StatesTaking people
- Upstate Clinical Research Associates, LLCWilliamsville, United StatesNot yet recruiting
- Conquest Research-Winter ParkWinter Park, United StatesTaking people
- New England Regional Headache Center, Inc.Worcester, United StatesNot yet recruiting
About the trial
What the trial wants to find out
Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine attacks in adults and for the preventive treatment of episodic migraine in adults when administered every other day. This study evaluates once daily rimegepant for the preventive treatment of chronic migraine.
Read full original descriptionShow less
After a 28-day observation period without study intervention, eligible participants will be randomized in a 1:1 ratio to receive either rimegepant 75 mg orally disintegrating tablet (ODT) or matching placebo once daily for 12 weeks under double-blind conditions. Participants who remain eligible at the end of the double-blind treatment phase will enter a 12-week open-label treatment period, during which all participants will receive open-label rimegepant 75 mg once daily. During this period, participants may also take an additional rimegepant tablet for the acute treatment of breakthrough migraine attacks, up to 10 doses per month. A 28-day follow-up period completes the approximately 32-week study.
The primary objective of the study is to determine whether once-daily rimegepant is more effective than placebo in reducing monthly migraine days relative to the observation period in adults with chronic migraine. Secondary objectives include evaluating differences between rimegepant and placebo in migraine responder rates, headache severity, acute migraine medication use, quality of life, work productivity, cognitive functioning, and safety and tolerability.
Approximately 400 adults aged 18 years or older with a diagnosis of chronic migraine for at least 1 year will be enrolled at multiple study sites.
The 2 groups in the trial
- Rimegepant 75 mg orally disintegrating tablet (ODT) once dailyTreatment being tested
Participants will receive rimegepant 75 mg orally disintegrating tablet (ODT) once daily during the 12-week double-blind treatment phase. Eligible participants may subsequently enter a 12-week open-label extension phase and receive open-label rimegepant 75 mg once daily. During the open-label extension phase, participants may also take an additional dose of rimegepant 75 mg for the acute treatment of breakthrough migraine attacks, up to 10 doses per month.
Treatment: Rimegepant
- Matching placebo once daily for 12 weeks during the double-blind treatment phasePlacebo, for comparison
Participants will receive matching placebo once daily during the 12-week double-blind treatment phase. Eligible participants may subsequently enter a 12-week open-label extension phase and receive open-label rimegepant 75 mg once daily. During the open-label extension phase, participants may also take an additional dose of rimegepant 75 mg for the acute treatment of breakthrough migraine attacks, up to 10 doses per month.
Treatment: Placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 3, DOUBLE-BLIND, RANDOMIZED, 2-ARM STUDY TO INVESTIGATE THE PREVENTION OF CHRONIC MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN PARTICIPANTS 18 YEARS OF AGE OR OLDER
- Plain-language title
- Tests rimegepant to prevent chronic migraine in adultsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 14 October 2026